John M Goldman

John M Goldman

UNVERIFIED PROFILE

Are you John M Goldman?   Register this Author

Register author
John M Goldman

John M Goldman

Publications by authors named "John M Goldman"

Are you John M Goldman?   Register this Author

100Publications

2323Reads

50Profile Views

Treating chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Acta Haematol 2013 13;130(3):192-5. Epub 2013 Jun 13.

Section of Haematology, Division of Experimental Medicine, Department of Medicine, Imperial College, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000351957DOI Listing
December 2013

Chronic myeloid leukemia in India.

Authors:
John M Goldman

Indian J Med Paediatr Oncol 2013 Jul;34(3):147-8

Department of Haematology, Imperial College London, UK E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0971-5851.123700DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902609PMC
July 2013

The significance of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:
John M Goldman

Biol Blood Marrow Transplant 2013 May 1;19(5):679-80. Epub 2013 Mar 1.

Department of Haematology, Imperial College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.02.016DOI Listing
May 2013

Ponatinib for chronic myeloid leukemia.

Authors:
John M Goldman

N Engl J Med 2012 Nov;367(22):2148-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1210796DOI Listing
November 2012

Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.

J Natl Compr Canc Netw 2012 Oct;10 Suppl 3:S1-S13

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2012.0184DOI Listing
October 2012

Is imatinib still an acceptable first-line treatment for CML in chronic phase?

Oncology (Williston Park) 2012 Oct;26(10):901-7

Department of Haematology, Imperial College London, United Kingdom.

View Article

Download full-text PDF

Source
October 2012

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

Blood 2012 Jul 29;120(2):291-4. Epub 2012 May 29.

Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-01-407486DOI Listing
July 2012

BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.

Clin Cancer Res 2011 Nov 8;17(21):6812-21. Epub 2011 Sep 8.

Oncology, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-0396DOI Listing
November 2011

Three decades of transplantation for chronic myeloid leukemia: what have we learned?

Blood 2011 Jan 21;117(3):755-63. Epub 2010 Oct 21.

Department of Haematology, Imperial College at Hammersmith Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-08-301341DOI Listing
January 2011

Comments on the Affordable Care Act and the future of clinical medicine.

Ann Intern Med 2011 Jan;154(2):140-1; discussion 143-4; author reply 144

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/0003-4819-154-2-201101180-00027DOI Listing
January 2011

Chronic myeloid leukemia: a historical perspective.

Authors:
John M Goldman

Semin Hematol 2010 Oct;47(4):302-11

Department of Haematology, Imperial College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2010.07.001DOI Listing
October 2010

Initial treatment for patients with CML.

Authors:
John M Goldman

Hematology Am Soc Hematol Educ Program 2009 :453-60

Department of Hematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2009.1.453DOI Listing
March 2010

Chronic myeloid leukemia: reversing the chronic phase.

Authors:
John M Goldman

J Clin Oncol 2010 Jan 14;28(3):363-5. Epub 2009 Dec 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.5587DOI Listing
January 2010

Treatment strategies for CML.

Authors:
John M Goldman

Best Pract Res Clin Haematol 2009 Sep;22(3):303-13

Department of Haematology, Imperial College London, Du Cane Road, London W12 0NN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2009.08.001DOI Listing
September 2009

Chronic myeloid leukemia stem cells: now on the run.

Authors:
John M Goldman

J Clin Oncol 2009 Jan 8;27(2):313-4. Epub 2008 Dec 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.2260DOI Listing
January 2009

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

J Clin Oncol 2008 Oct 21;26(29):4806-13. Epub 2008 Jul 21.

Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.16.9953DOI Listing
October 2008

Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.

Blood 2008 Sep 18;112(5):2163-6. Epub 2008 Jun 18.

Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-04-148130DOI Listing
September 2008

BCR-ABL in chronic myelogenous leukemia--how does it work?

Acta Haematol 2008 20;119(4):212-7. Epub 2008 Jun 20.

Department of Haematology, Imperial College at Hammersmith Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000140633DOI Listing
August 2008

How I treat chronic myeloid leukemia in the imatinib era.

Authors:
John M Goldman

Blood 2007 Oct 12;110(8):2828-37. Epub 2007 Jul 12.

Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2007-04-03
Publisher Site
http://dx.doi.org/10.1182/blood-2007-04-038943DOI Listing
October 2007

Advances in CML.

Authors:
John M Goldman

Clin Adv Hematol Oncol 2007 Apr;5(4):270-2, 292

Hematology Branch, Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
April 2007

Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.

Clin Lymphoma Myeloma 2007 Mar;7 Suppl 2:S81-4

Division of Hematology and Stem Cell Transplantation, University of Texas Southwestern Medical School, Dallas 75390, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clm.2007.s.006DOI Listing
March 2007

Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.

Clin Lymphoma Myeloma 2007 Mar;7 Suppl 3:S95-101

Division of Hematology and Stem Cell Transplantation, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clm.2007.s.008DOI Listing
March 2007

Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

Blood 2006 Jan 6;107(1):205-12. Epub 2005 Sep 6.

Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2005-05-21
Publisher Site
http://dx.doi.org/10.1182/blood-2005-05-2155DOI Listing
January 2006

Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?

Front Biosci 2006 Jan 1;11:198-208. Epub 2006 Jan 1.

Division of Hematology and Oncology, University of Massachusetts Medical School, Worcester, MA 01655, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2741/1791DOI Listing
January 2006

Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.

Front Biosci 2006 Jan 1;11:209-20. Epub 2006 Jan 1.

Division of Hematology and Oncology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2741/1792DOI Listing
January 2006

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Cancer Res 2005 Oct;65(19):8912-9

Department of Haematology, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-0076DOI Listing
October 2005

Pneumocystis carinii pneumonia infection in a patient with known chronic mucocutaneous candidiasis.

Respirology 2005 Jun;10(3):399-401

Department of Respiratory Medicine, Torbay Hospital, Torquay, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1440-1843.2005.00700.xDOI Listing
June 2005

Immune therapy of chronic myelogenous leukemia.

Leuk Res 2005 May;29(5):583-6

Center for Advanced Studies in Leukemia, 11693 San Vicente Boulevard, Suite 335, Los Angeles, CA 90049-5105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2004.11.005DOI Listing
May 2005

A unifying mutation in chronic myeloproliferative disorders.

Authors:
John M Goldman

N Engl J Med 2005 Apr;352(17):1744-6

Hematology Branch of the National Heart, Lung, and Blood Institute, Bethesda, Md, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMp058083DOI Listing
April 2005

Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.

Chin Med J (Engl) 2004 Jul;117(7):968-71

Jiangsu Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou 215006, China.

View Article

Download full-text PDF

Source
July 2004

Chronic myeloid leukemia: current status and controversies.

Oncology (Williston Park) 2004 Jun;18(7):837-44, 847; discussion 847-50, 853-4

Department of Haematology, Hammersmith Hospital at the Imperial College London, London, United Kingdom.

View Article

Download full-text PDF

Source
June 2004

IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation.

Blood 2004 Jan 25;103(2):717-24. Epub 2003 Sep 25.

Department of Immunology, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-01-0192DOI Listing
January 2004

Chronic myeloid leukemia-still a few questions.

Authors:
John M Goldman

Exp Hematol 2004 Jan;32(1):2-10

Imperial College London, England, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2003.10.001DOI Listing
January 2004

Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.

Exp Hematol 2003 Nov;31(11):1073-80

Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK.

View Article

Download full-text PDF

Source
November 2003

Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.

Br J Haematol 2003 Oct;123(1):106-9

Department of Haematology, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1365-2141.2003.04561.xDOI Listing
October 2003

Chronic myeloid leukemia--advances in biology and new approaches to treatment.

N Engl J Med 2003 Oct;349(15):1451-64

Department of Haematology, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra020777DOI Listing
October 2003

Myeloproliferative and myelodysplastic syndromes: the future.

Authors:
John M Goldman

Hematol Oncol Clin North Am 2003 Oct;17(5):1261-9

Department of Haematology, Imperial College at Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0889-8588(03)00092-3DOI Listing
October 2003

Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.

Int J Cancer 2003 Sep;106(3):455-7

Department of Hematology, Faculty of Medicine Imperial College of Science, Technology and Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.11247DOI Listing
September 2003

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

Blood 2003 Aug 10;102(3):1064-9. Epub 2003 Apr 10.

Department of Hematology, Faculty of Medicine Imperial College, Hammersmith Hospital, Du Cane Road, W12 0NN, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-02-0380DOI Listing
August 2003

Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons.

Br J Haematol 2003 Aug;122(3):424-9

Leukaemia Research Fund Centre, Imperial College Faculty of Medicine, Hammersmith Campus, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1365-2141.2003.04451.xDOI Listing
August 2003

Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.

Transplantation 2003 May;75(9):1429-36

Department of Immunology and Haematology, Imperial College of Science Technology and Medicine, Faculty of Medicine, Hammersmith Hospital, London.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.TP.0000061516.57346.E8DOI Listing
May 2003

Clinical decisions for chronic myeloid leukemia in the imatinib era.

Semin Hematol 2003 Apr;40(2 Suppl 2):98-103; discussion 104-13

Department of Haematology, Imperial College London at Hammersmith Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/shem.2003.50049DOI Listing
April 2003

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.

Eur J Haematol 2003 Jan;70(1):34-42

Department of Haematology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1034/j.1600-0609.2003.02823.xDOI Listing
January 2003

Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase.

Authors:
John M Goldman

Semin Hematol 2003 Jan;40(1 Suppl 1):10-7

Department of Haematology, Imperial College Faculty of Medicine, Hammersmith Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/shem.2003.50028DOI Listing
January 2003